

1                   **HOUSE OF REPRESENTATIVES - FLOOR VERSION**

2                               STATE OF OKLAHOMA

3                               2nd Session of the 59th Legislature (2024)

4   ENGROSSED SENATE  
5   BILL NO. 1344

By: Rosino of the Senate

and

West (Josh) and Munson of  
the House

6  
7  
8  
9  
10       An Act relating to nonopioid alternatives; directing  
11       specified agencies to seek certain funding  
12       opportunities and provide certain assistance with  
13       opioid grant awards; defining term; granting certain  
14       protection to nonopioid drugs relating to Medicaid  
15       drug formulary; prohibiting certain denial of  
16       coverage; providing certain construction; amending 74  
17       O.S. 2021, Section 30.5, as amended by Section 1,  
18       Chapter 75, O.S.L. 2022 (74 O.S. Supp. 2023, Section  
19       30.5), which relates to definitions used in the  
20       Political Subdivisions Opioid Abatement Grants Act;  
21       broadening approved purposes; providing for  
22       codification; and providing an effective date.

23  
24   BE IT ENACTED BY THE PEOPLE OF THE STATE OF OKLAHOMA:

SECTION 1.       NEW LAW       A new section of law to be codified  
in the Oklahoma Statutes as Section 2-402 of Title 43A, unless there  
is created a duplication in numbering, reads as follows:

1       The Department of Mental Health and Substance Abuse Services,  
2       the State Department of Health, and the Oklahoma Health Care  
3       Authority shall:

4       1. Collaborate to seek funding opportunities for educational  
5       and health care services related to nonopioid alternatives; and

6       2. Assist, upon request, political subdivisions that receive  
7       opioid grant awards under the Political Subdivisions Opioid  
8       Abatement Grants Act with the development and implementation of  
9       educational and health care services related to nonopioid  
10      alternatives.

11      SECTION 2.       NEW LAW       A new section of law to be codified  
12      in the Oklahoma Statutes as Section 5031 of Title 63, unless there  
13      is created a duplication in numbering, reads as follows:

14      A. As used in this section, "contracted entity" has the same  
15      meaning as provided by Section 4002.2 of Title 56 of the Oklahoma  
16      Statutes.

17      B. In establishing and maintaining the formulary for the state  
18      Medicaid program, the Oklahoma Health Care Authority shall ensure  
19      that no nonopioid drug approved by the United States Food and Drug  
20      Administration (FDA) for the treatment or management of pain shall  
21      be disadvantaged or discouraged by either the Authority or a  
22      contracted entity with respect to coverage on the formulary relative  
23      to any opioid or narcotic drug for the treatment or management of  
24      pain.

1 C. When a contracted provider prescribes an FDA-approved  
2 nonopioid drug for the treatment or management of pain, the  
3 Authority or a contracted entity shall not deny coverage of the  
4 nonopioid drug in favor of an opioid drug.

5 D. This section does not preclude opioid drugs from being  
6 preferred over other opioid drugs or nonopioid drugs from being  
7 preferred over other nonopioid drugs.

8 SECTION 3. AMENDATORY 74 O.S. 2021, Section 30.5, as  
9 amended by Section 1, Chapter 75, O.S.L. 2022 (74 O.S. Supp. 2023,  
10 Section 30.5), is amended to read as follows:

11 Section 30.5. As used in the Political Subdivisions Opioid  
12 Abatement Grants Act:

13 1. "Approved purpose" and "approved purposes" mean evidence-  
14 based, forward-looking strategies, programming and services used to:

- 15 a. expand the availability of treatment for individuals  
16 affected by opioid use disorders, co-occurring  
17 substance use disorders and mental health issues,
- 18 b. develop, promote and provide evidence-based opioid use  
19 prevention strategies,
- 20 c. provide opioid use disorder and co-occurring substance  
21 use disorder avoidance and awareness education,
- 22 d. decrease the oversupply of licit and illicit opioids,
- 23 e. support recovery from addiction services performed by  
24 qualified and appropriately licensed providers,

- 1 f. treat opioid use, abuse and disorders including early  
2 intervention screening, counseling and support,  
3 g. support individuals in treatment and recovery from  
4 opioid use, abuse and disorder,  
5 h. provide programs or services to connect individuals  
6 with opioid use, abuse or disorder, or who are at risk  
7 of developing opioid use disorder, co-occurring  
8 substance use disorder and mental health issues, with  
9 treatment and counseling programs and services,  
10 i. address the needs of individuals who are involved, or  
11 who are at risk of becoming involved, in the criminal  
12 justice system due to opioid use, abuse or disorder  
13 through programs or services in municipal and county  
14 criminal judicial systems including prearrest and  
15 postarrest diversion programs, pretrial services and  
16 drug or recovery courts,  
17 j. address the needs of pregnant or parenting women with  
18 opioid use, abuse or disorder and their families,  
19 k. address the needs of parents and caregivers caring for  
20 babies with neonatal abstinence syndrome,  
21 l. support efforts to prevent overprescribing and ensure  
22 appropriate prescribing and dispensing of opioids,  
23  
24

- 1           m.    support efforts to discourage or prevent misuse of  
2                   opioids including the oversupply of licit and illicit  
3                   opioids,
- 4           n.    support efforts to prevent or reduce overdose deaths  
5                   or other opioid-related harms including through  
6                   increased availability and distribution of naloxone  
7                   and other drugs that treat overdoses for use by first  
8                   responders, persons who have experienced an overdose  
9                   event, families, schools, community-based service  
10                  providers, social workers and other members of the  
11                  public,
- 12          o.    reimburse or fund law enforcement and emergency  
13                  responder expenditures relating to the opioid epidemic  
14                  including costs of responding to emergency medical or  
15                  police calls for service, equipment, treatment or  
16                  response alternatives, mental health response training  
17                  and training for law enforcement and emergency  
18                  responders as to appropriate practices and precautions  
19                  when dealing with opioids or individuals who are at  
20                  risk of opioid overdose or death,
- 21          p.    reimburse attorney fees and allowable expenses  
22                  directly related to opioid litigation incurred as part  
23                  of legal services agreements entered into before May  
24                  21, 2020,

- 1           q.    support efforts to provide leadership, planning and  
2                coordination to abate the opioid epidemic through  
3                activities, programs or strategies for prevention and  
4                recovery models including regional intergovernmental  
5                efforts and not-for-profit agency support,  
6           r.    support education of youths regarding the dangers of  
7                opioid use, abuse and addiction,  
8           s.    fund training relative to any approved purpose,  
9           t.    monitor, surveil and evaluate opioid use, abuse or  
10               disorder, ~~or~~  
11           u.   provide educational and health care services related  
12               to nonopioid treatment alternatives, or  
13           v.   provide opioid abatement as identified by the Oklahoma  
14               Opioid Abatement Board as consistent with the purpose  
15               of the Political Subdivisions Opioid Abatement Grants  
16               Act.

17   Provided that, such strategies, programming and services occurred on  
18   or after January 1, 2015;

19       2.    "Board" means the Oklahoma Opioid Abatement Board;

20       3.    "Eligible participant" means any political subdivision  
21   impacted by the opioid crisis;

22       4.    "Nonapproved purpose" and "nonapproved purposes" mean  
23   strategies, programming and services not falling within the  
24

1 definition of approved purpose or approved purposes as defined in  
2 this section;

3 5. "Opioid funds" means all monetary amounts obtained through a  
4 settlement or judgment by the Attorney General on behalf of this  
5 state related to opioid litigation involving pharmaceutical supply  
6 chain participants including the Purdue Political Subdivisions Fund  
7 but excluding all other funds received pursuant to the Purdue  
8 Settlement Agreement;

9 6. "Opioid grant awards" means grants funded from the Oklahoma  
10 Opioid Abatement Revolving Fund, awarded pursuant to the provisions  
11 of the Political Subdivisions Opioid Abatement Grants Act;

12 7. "Pharmaceutical supply chain" means the process and channels  
13 through which controlled substances are manufactured, marketed,  
14 promoted, distributed or dispensed;

15 8. "Pharmaceutical supply chain participant" means any entity  
16 that engages in or has engaged in the manufacture, marketing,  
17 promotion, distribution or dispensing of an opioid analgesic;

18 9. "Political subdivision" and "political subdivisions" have  
19 the same meaning as provided in subparagraphs a, b, c and d of  
20 paragraph 11 of Section 152 of Title 51 of the Oklahoma Statutes;

21 10. "Purdue Political Subdivision Fund" means the Twelve  
22 Million Five Hundred Thousand Dollars (\$12,500,000.00) plus any  
23 interest accrued thereon received from the Revive Oklahoma Health  
24 Foundation consisting of funds from the Purdue Settlement Agreement

1 designed for distribution to political subdivisions which have  
2 executed a release of legal claims as required by the Purdue  
3 Settlement Agreement; and

4 11. "Purdue Settlement Agreement" means the settlement  
5 agreement entered into by this state and Purdue Pharma L.P., Purdue  
6 Pharma, Inc. and the Purdue Frederick Company on March 26, 2019, and  
7 approved by the Court on April 2, 2019.

8 SECTION 4. This act shall become effective November 1, 2024.

9  
10 COMMITTEE REPORT BY: COMMITTEE ON APPROPRIATIONS AND BUDGET, dated  
11 04/11/2024 - DO PASS.  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24